step 8 semaglutide Clinical trials of subcutaneous in overweight and obese Semaglutide as a GLP-1 Agonist:

Patients should avoid injecting into the same spot repeatedly and maintain a rotation schedule, waiting at least one week before returning to a previously used site

Notably, DTC telehealth models fit naturally with conditions requiring long-term management, such as type 2 diabetes and obesity

It is currently undergoing Phase 3 clinical trials and has not yet received FDA approval

Resources We Trust Cleveland Clinic: GLP-1 Agonists Mayo Clinic: Considering GLP-1 Medications

After up to a year: The patients who took the medication had significantly greater improvements in RA disease activity and pain than the control group